Massiver Turnaround bevorstehend?

Gestern rein mit einer kleinen Posi bei $.35 und heute schon hoch. Meines Erachtens wurde die zu sehr abgestraft. Heute dann die Meldung, dass das MM keine Dilution zu Lasten der stockholder vornehmen möchte und Warrantsholder aus der Firmenkasse auszahlt. Mal sehen wo es endet. Produkte und letzter ER schienen ok. Viel Glück, biotech  

 

man beachte das Kursziel - 6.50 USD, Produkte sind mindestens wenn nicht besser als die der Konkurrenz aber günstiger  

http://seekingalpha.com/article/...-infectious-disease-testing-market  

wieviel Shares sind im Umlauf?  

7,29 mil laut Yahoo Finance  

Suche gerade alle Infos bezüglich des Kursverfalles.
 

bin heute auch mit einer Posi zu 0,3975 rein. Mal schauen wie sich der Kurs entwickelt.  

Um die .40 sieht es nach Konsolidierung aus.  

 

eben auch mal eine Posi zugelegt.

Mal schauen .

50 % des Kursziel von Seeking Alpha würden mir ja schon reichen, bin bescheiden :-)  

was bedeutet delisting warrents c?
Kann mir jmnd Infos drüber geben.

http://www.wsnewspublishers.com/...r-momo-inc-adr-nasdaqmomo/1526520/  

Hast Du jetzt was rausgefunden, warum der Absturz ?

Das mit der Shareanzahl lt. Yahoo (7,29 Mio.) kommt mir auch irgendwie merkwürdig vor.

Dann müßten die ja gestern gut 2 mal durchgehandelt worden sein wenn ich sehe, daß alleine an der NASDAQ rd. 13,7 Mio. Shares gehandelt worden sind (gut sicherlich einige doppelt und dreifach, aber trotzdem).

Da ist doch auch einiges an Warrents in letzter Zeit gelaufen ?  

 

Warum der Absturz die tage?
Bitte um Info  

Der Absturz war durch eine Warrants-Finanzierung verursacht. Das Unternehmen möchte jedoch, um eine Dilution zu vermeiden, einen noch nicht näher spezifizierten Anteil aus der Portokasse an die Warrants-holder zahlen. Hinzu kommt, dass die Aktie massiv von Shortsellern ins Visier genommen wurde. Es gibt keinen offensichtlichen Anlass für diese heftige Reaktion. Die Zahlen sehen sonst ok aus (soweit ich das beurteilen kann), das Interesse an den Geräten steigt und sie sind günstiger als die Konkurrenz bei mindestens gleichwertiger Qualität und Funktionsweise, wenn nicht besser. Für mich ein echter Rebound-Kandidat. Ich hoffe, sie beschert uns allen hübsche Gewinne. VG, biotech

PS: Keine Handelsempfehlung! Falls jemand kursrelevante News/Fakten findet, bitte posten.  

Great Basin Submits 510(k) Application to the FDA for Staph ID/R Blood Culture

14:20 31.08.15

SALT LAKE CITY --(BUSINESS WIRE)--

Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that the Company has submitted its Staph ID/R Blood Culture Panel to the U.S. Food & Drug Administration (FDA) for 510(k) clearance. The submission of the Staph ID/R panel, the Company’s first multiplex panel, comes after the successful completion of a clinical trial that met all of Great Basin’s clinical objectives. Great Basin offers the first and only molecular diagnostic platform capable of low-plex tests, as well as multiplex and direct-from-specimen panels.

The Great Basin Staph ID/R Blood Culture Panel is a sample-to-result, automated, molecular multiplex panel that detects Staph aureus and two other staph species along with the mecA gene, a major drug resistance marker that confers resistance to methicillin and creates the superbug MRSA. In addition to Staph aureus, the panel also detects Staphylococcus lugdunensis and Staphylococcus epidermidis. The remaining staph species are detected as a group and identified as “Staphylococcus present.” When compared to traditional blood culture methods, results of this panel are expected to allow for a faster diagnosis and therefore a more timely appropriate therapy, which is associated with improved patient outcomes, lower treatment costs, and shorter length of hospital stay for affected patents.

“The successful trial completion and submission to the FDA of our Staph ID/R panel marks a significant milestone for Great Basin, and a critical advancement for our customers and hundreds of thousands of patients in the U.S. who are affected by staph bloodstream infections – including the deadly superbug MRSA – every year,” said Ryan Ashton, co-founder and Chief Executive Officer. “We are excited to submit our first multiplex panel to the FDA, and look forward to the value this test will add to the Great Basin platform, further setting us apart from other solutions in the molecular diagnostics space with superior scalability and cost efficiency.”

Ryan continued: “I am proud of the determination of the Great Basin team, which continues to execute at the highest level, delivering on the promise to provide current and future customers with a robust menu of easy-to-use and cost effective tests and panels. This panel will be higher value than our low-plex tests and increases our potential revenue per customer by offering higher revenue per test than either our C. diff test, or our GBS test.”

Once approved and commercially available, hospital and lab technicians can run the new multiplex panel on the same analyzer used to perform Great Basin’s commercially available low-plex tests for Clostridium difficile (C. diff) and Group B Streptococcus (GBS). Great Basin expects to offer the panel at a significantly lower cost than other blood panels on the market today, making fast, easy diagnosis of staph-caused blood sepsis affordable for the small to medium hospitals the Company targets. The Company’s unique scale to run a broad assay menu further enhances the economics for its customers, while also allowing Great Basin to grow their business with new and existing customers.

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.

Forward-Looking Statements

This press release includes forward-looking statement regarding the Staph ID/R Blood Culture Panel and its effects upon the Company. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization, including the Staph ID/R Blood Culture Panel mentioned herein; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150831005609/en/
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.  

bin auch mal rein,
mal sehen wie es weiter geht.  

Shorts am covern oder einfach nur Manipulation?  

eben verdoppelt.

Einreichung FDA kann ja nicht sooooo schlecht sein wie der Kurs es meint uns vorzuspiegeln.

Wenn das Ding sooo geshortet wird, event. bekommen einige von denen heute kalte Füsse.

Ansonsten, irgendwann sollte ein Turnaround stattfinden und sei es nur technischer Natur.  

ist das ein eindeutiger Bankrott-Kandidat!
Wer auch sein gesamtes Kapital verlieren möchte so wie ich, der investiere hier.
Mein nächster Nachkauf bei $0,2 danach gehts bewiesenermaßen immer nochmal 50 % abwärts!
Damit kann ich immerhin die nächsten Hochhäuser tapezieren, auch gut. Gewinn - Fehlanzeige  

Weißt Du wieviel die in der Portokasse (sprich Cash) haben ?

Finde darüber irgendwie nichts vernünftiges.  

Habe auch noch keine eindeutige Angabe dazu gefunden. Aber ich habe soeben dazugekauft. Die Manipulation geht mir am A.... vorbei. Habe auch eine eMail von Brian Marckx, CFA und Autor auf Seeking Alpha erhalten: auf meine Frage hin, was er von den letzten Entwicklungen rund um GSBN halte, antwortete er dass es traurig wäre, mit welchen Investoren deren Bank die Finanzierung durchgeführt habe und diese natürlich sobald sie die Chance zur Umwandlung der Warrants sahen, diese auch ergriffen haben - dumped. Aber die Dilution habe er bei seiner letzten Analyse einberechnet und halte auch an seiner Kaufempfehlung fest. PT nach wie vor bei $6.50.
 

Installed Base Expected To More Than Double By Year-End: The $30M+ raised from the IPO in October and the follow-on offering in March 2015 has allowed GBSN to begin streamlining manufacturing, fund the late-stage pipeline and ramp analyzer production. 150 new analyzers have already been built, and another 250 are expected to be completed by mid-year. Hospitals appear to be highly receptive to the technology with all of the first batch of 150 expected to be either under evaluation by prospective customers or already being used by purchasing customers by the end of April. The next 250 would then begin rolling out to evaluation sites in the summer. Management aims to have 170-180 U.S. purchasing customers by the current year-end, up from 84 at the end of 2014 (over 100% growth).

und

Pro forma for issuance of common shares subsequent to the end of the quarter, cash balance at Q1 quarter-end was approximately $22 million. Assuming our cash burn estimates are accurate, GBSN will exit 2015 with approximately $9M in cash (assuming no additional capital raises during the year), and will need to raise additional capital by sometime in 2016. Our modeled outstanding share count incorporates the assumption that future capital raises come in the form of common equity (or convertible debt, which is subsequently converted to equity).

Also beenden die wohl das Jahr 2015 mit 9 mil USD cash.

 

hab ja auch dazugekauft.

Schade, leider nicht am Tiefstpunkt, aber immerhin zu 0,28 € .